Beyond the health impact, obesity and high body mass index (BMI) pose a growing burden for European economies, costing billions of euros annually through direct and indirect costs, according to a new pharmaceutical industry report.
The total annual costs represent 0.7% to 1.4% of national GDP across Germany, France, Italy, Spain, Ireland, Greece, Romania and the United Kingdom, the countries analysed in the study conducted by the Office of Health Economics (OHE) for the pharmaceutical lobby EFPIA.
